Cardiorenal Translational
Laboratory
PUBLICATIONS
Articles published by Gema Ruiz-Hurtado, to see the lastest articles click here:
https://pubmed.ncbi.nlm.nih.gov/?term=ruiz-hurtado+g&sort=date
2021
106. Early renal and vascular damage within the normoalbuminuria condition. Santiago-Hernandez A, Martin-Lorenzo M, Martínez PJ, Gómez-Serrano M, Lopez JA, Cannata P, Esteban V, Heredero A, Aldamiz-Echevarria G, Vázquez J, Ruiz-Hurtado G, Barderas MG, Segura J, Ruilope LM, Alvarez-Llamas G. J Hypertens. 2021 Nov 1;39(11):2220-2231.
105. May Measurement Month 2019: an analysis of blood pressure screening results from Spain. Molinero A, Calvo E, Beaney T, Day E, Prats-Mas R, Fornos JA, Mera-Gallego I, Tous S, de Andrés NF, Rodilla E, Gijón T, Pérez-Manchon D, Poulter NR, Ruiz-Hurtado G, Ruilope LM. Eur Heart J Suppl. 2021 May 20;23(Suppl B):B138-B140.
104. CARDIOVASCULAR RISK STRATIFICATION BASED ON OXIDATIVE STRESS FOR EARLY DETECTION OF PATHOLOGY. Corbacho-Alonso N, Baldan-Martin M, Lopez JA, Rodriguez- Sanchez E, Martinez PJ, Mourino-Alvarez L, Sastre-Oliva T, Cabrera M, Calvo E, Padial LR, Vazquez J, Vivanco F, Alvarez-Llamas G, Ruiz-Hurtado G, Ruilope LM, Barderas MG. Antioxid Redox Signal. 2021 May 26.
103. Ca2+ mishandling in heart failure: potential targets. Val-Blasco A, Gil-Fernández M, Rueda A, Pereira L, Delgado C, Smani T, Ruiz Hurtado G, Fernández-Velasco M. Acta Physiol (Oxf). 2021 May 22:e13691.
102. ADEQUATE BLOOD PRESSURE CONTROL UNATTAINABLE WITHOUT ADEQUATE RECOGNITION AND TREATMENT OF PRIMARY ALDOSTERONISM. Ruilope LM, Ruiz-Hurtado G, Tamargo J. Trends Cardiovasc Med. 2021 Apr 16:S1050-1738(21)00047-5.
101. An Overview of FGF-23 as a Novel Candidate Biomarker of Cardiovascular Risk. Vázquez-Sánchez S, Poveda J, Navarro-García JA, González-Lafuente L, Rodríguez-Sánchez E, Ruilope LM, Ruiz-Hurtado G. Front Physiol. 2021 Mar 9;12:632260.
100. TWEAK-Fn14 as a common pathway in the heart and the kidneys in cardiorenal syndrome. Poveda J, Vázquez-Sánchez S, Sanz AB, Ortiz A, Ruilope LM, Ruiz-Hurtado G. J Pathol. 2021 Jan 29. doi: 10.1002/path.5631.
99. Analysis of global oxidative status using multimarker scores reveals a specific association between renal dysfunction and diuretic therapy in older adults. Rodríguez-Sánchez E, Navarro-García JA, Aceves-Ripoll J, González-Lafuente L, Corbacho-Alonso N, Baldan-Martín M, Madruga F, Alvarez-Llamas G, Barderas MG, Ruilope LM, Ruiz-Hurtado G. J Gerontol A Biol Sci Med Sci. 2021 Jan 10:glab012.
98. Lifestyle interventions for the prevention and treatment of hypertension. Valenzuela PL, Carrera-Bastos P, Gálvez BG, Ruiz-Hurtado G, Ordovas JM, Ruilope LM, Lucia A. Nat Rev Cardiol. 2021 Apr;18(4):251-275.
2020
97. Are the guidelines of the ISH devoted to a population not contemplated in the ACC/AHA guidelines? Ruilope LM, Ruiz-Hurtado G, Lucia A. Int J Cardiol Hypertens. 2020 Nov 18;7:100068.
96. Systemic lupus erythematosus and cardiovascular disease. Ruilope LM, Ruiz-Hurtado G. Int J Cardiol Hypertens. 2020 Nov 3;7:100065.
95. Age and blood pressure goal in women with prior coronary events. Ruilope LM, Ruiz-Hurtado G. Int J Cardiol Hypertens. 2020 Oct 20;7:100059.
94. Exercise Reduces Ambulatory Blood Pressure in Patients With Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Saco-Ledo G, Valenzuela PL, Ruiz-Hurtado G, Ruilope LM, Lucia A. J Am Heart Assoc. 2020 Dec 15;9(24):e018487.
93. Oxidized Low-Density Lipoprotein Associates with Ventricular Stress in Young Adults and Triggers Intracellular Ca2+ Alterations in Adult Ventricular Cardiomyocytes. Rodríguez-Sánchez E, Navarro-García JA, González-Lafuente L, Aceves-Ripoll J, Vázquez-Sánchez S, Poveda J, Mercado-García E, Corbacho-Alonso N, Calvo-Bonacho E, Fernández-Velasco M, Álvarez-Llamas G, Barderas MG, Ruilope LM, Ruiz-Hurtado G. Antioxidants (Basel). 2020 Dec 1;9(12):1213.
92. Genetic Deletion of NOD1 Prevents Cardiac Ca2+ Mishandling Induced by Experimental Chronic Kidney Disease. Gil-Fernández M, Navarro-García JA, Val-Blasco A, González-Lafuente L, Martínez JC, Rueda A, Tamayo M, Morgado JL, Zaragoza C, Ruilope LM, Delgado C, Ruiz-Hurtado G, Fernández-Velasco M. Int J Mol Sci. 2020 Nov 23;21(22):8868.
91. Editorial: Evolving Picture of Calcium Handling in Cardiac Disease.Ruiz-Hurtado G, Rueda A, Pereira L, Fernández-Velasco M. Front Physiol. 2020 Sep 4;11:1013.
90. Urinary metabolic signatures reflect cardiovascular risk in the young, middle-aged, and elderly populations. Martinez PJ, Agudiez M, Molero D, Martin-Lorenzo M, Baldan-Martin M, Santiago-Hernandez A, García-Segura JM, Madruga F, Cabrera M, Calvo E, Ruiz-Hurtado G, Barderas MG, Vivanco F, Ruilope LM, Alvarez-Llamas G. J Mol Med (Berl). 2020 Nov;98(11):1603-1613.
89. Enhanced Klotho availability protects against cardiac dysfunction induced by uraemic cardiomyopathy by regulating Ca2+ handling. Navarro-García JA, Rueda A, Romero-García T, Aceves-Ripoll J, Rodríguez-Sánchez E, González-Lafuente L, Zaragoza C, Fernández-Velasco M, Kuro-O M, Ruilope LM, Ruiz-Hurtado G. Br J Pharmacol. 2020 Oct;177(20):4701-4719.
88. Prediction of the early response to spironolactone in resistant hypertension by the combination of matrix metalloproteinase-9 activity and arterial stiffness parameters. Rodríguez-Sánchez E, Navarro-García JA, Aceves-Ripoll J, González-Lafuente L, Baldan-Martin M, de la Cuesta F, Alvarez-Llamas G, Barderas MG, Segura J, Ruilope LM, Ruiz-Hurtado G. Eur Heart J Cardiovasc Pharmacother. 2020 Jul 14:pvaa086.
87. Renin-angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs. Ruilope LM, Tamargo J, Ruiz-Hurtado G. Eur Heart J. 2020 Jun 7;41(22):2067-2069.
86. Novel molecular plasma signatures on cardiovascular disease can stratify patients throughout life. Corbacho-Alonso N, Baldán-Martín M, López JA, Rodríguez-Sánchez E, Martínez PJ, Mourino-Alvarez L, Martin-Rojas T, Sastre-Oliva T, Madruga F, Vázquez J, Padial LR, Alvarez-Llamas G, Vivanco F, Ruiz-Hurtado G, Ruilope LM, Barderas MG. J Proteomics. 2020 Jun 30;222:103816.
85. Management of hypertension in the very old: aggressive reduction of blood pressure is harmful in most patients. Ruilope LM, Ruiz-Hurtado G. J Hum Hypertens. 2020 Sep;34(8):557-559.
84. Variations in Circulating Active MMP-9 Levels During Renal Replacement Therapy. Rodríguez-Sánchez E, Navarro-García JA, Aceves-Ripoll J, Abarca-Zabalía J, Susmozas-Sánchez A, Bada-Bosch T, Hernández E, Mérida-Herrero E, Andrés A, Praga M, Fernández-Ruiz M, Aguado JM, Segura J, Ruilope LM, Ruiz-Hurtado G. Biomolecules. 2020 Mar 26;10(4):505.
83. Beneficial effects of paricalcitol on cardiac dysfunction and remodelling in a model of established heart failure. Tamayo M, Martín-Nunes L, Val-Blasco A, G M-Piedras MJ, Navarro-García JA, Lage E, Prieto P, Ruiz-Hurtado G, Fernández-Velasco M, Delgado C. Br J Pharmacol. 2020 Jul;177(14):3273-3290.
82. Differential metabolic profile associated with the condition of normoalbuminuria in the hypertensive population. Santiago-Hernandez A, Martinez PJ, Martin-Lorenzo M, Ruiz-Hurtado G, G Barderas M, Segura J, Ruilope LM, Alvarez-Llamas G. Nefrologia. 2020 Jul-Aug;40(4):440-445.
81. Finerenone Reduces Intrinsic Arterial Stiffness in Munich Wistar Frömter Rats, a Genetic Model of Chronic Kidney Disease. Gil-Ortega M, Vega-Martín E, Martín-Ramos M, González-Blázquez R, Pulido-Olmo H, Ruiz-Hurtado G, Schulz A, Ruilope LM, Kolkhof P, Somoza B, Kreutz R, Fernández-Alfonso MS. Am J Nephrol. 2020;51(4):294-303.
80. Early Posttransplant Mobilization of Monocytic Myeloid-derived Suppressor Cell Correlates With Increase in Soluble Immunosuppressive Factors and Predicts Cancer in Kidney Recipients. Utrero-Rico A, Laguna-Goya R, Cano-Romero F, Chivite-Lacaba M, Gonzalez-Cuadrado C, Rodríguez-Sánchez E, Ruiz-Hurtado G, Serrano A, Fernández-Ruiz M, Justo I, González E, Andrés A, Paz-Artal E. Transplantation. 2020 Dec;104(12):2599-2608.
79. On the need of the simultaneous control of arterial hypertension and diabetes mellitus. Ruilope LM, Rodriguez-Sánchez E, Ruiz-Hurtado G. J Clin Hypertens (Greenwich). 2020 Feb;22(2):221-222.
78. Intracellular calcium mishandling leads to cardiac dysfunction and ventricular arrhythmias in a mouse model of propionic acidemia. Tamayo M, Fulgencio-Covián A, Navarro-García JA, Val-Blasco A, Ruiz-Hurtado G, Gil-Fernández M, Martín-Nunes L, Lopez JA, Desviat LR, Delgado C, Richard E, Fernández-Velasco M. Biochim Biophys Acta Mol Basis Dis. 2020 Jan 1;1866(1):165586.
77. Resistant hypertension: new insights and therapeutic perspectives. Ruilope LM, Rodríguez-Sánchez E, Navarro-García JA, Segura J, Órtiz A, Lucia A, Ruiz-Hurtado G. Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(3):188-193.
2019
76. Oxidative Status before and after Renal Replacement Therapy: Differences between Conventional High Flux Hemodialysis and on-Line Hemodiafiltration. Navarro-García JA, Rodríguez-Sánchez E, Aceves-Ripoll J, Abarca-Zabalía J, Susmozas-Sánchez A, González Lafuente L, Bada-Bosch T, Hernández E, Mérida-Herrero E, Praga M, Ruilope LM, Ruiz-Hurtado G. Nutrients. 2019 Nov 17;11(11):2809.
75. Microalbuminuria and cardiorenal risk: old and new evidence in different populations. Márquez DF, Ruiz-Hurtado G, Segura J, Ruilope L. F1000Res. 2019 Sep 19;8:F1000 Faculty Rev-1659.
74. The endless story of markers of renal function and cardiovascular risk. Ruilope LM, Rodríguez-Sánchez E, Ruiz-Hurtado G. Eur Heart J. 2019 Nov 1;40(42):3494-3495.
73. Lifetime cardiovascular risk is associated with a multimarker score of systemic oxidative status in young adults independently of traditional risk factors. RodrÍguez-SÁnchez E, Navarro-GarcÍa JA, Aceves-Ripoll J, GonzÁlez-Lafuente L, Corbacho-Alonso N, Martinez P, Calvo-Bonacho E, Alvarez-Llamas G, Barderas MG, Ruilope LM, Ruiz-Hurtado G. Transl Res. 2019 Oct;212:54-66.
72. Proteomic investigations into hypertension: what's new and how might it affect clinical practice? Corbacho-Alonso N, Rodríguez-Sánchez E, Martin-Rojas T, Mouriño-Alvarez L, Sastre-Oliva T, Hernandez-Fernandez G, Padial LR, Ruilope LM, Ruiz-Hurtado G, Barderas MG. Expert Rev Proteomics. 2019 Jul;16(7):583-591.
71. Monotherapy still useful in a bunch of patients with arterial hypertension. Ruilope LM, Ruiz-Hurtado G. Int J Cardiol. 2019 Sep 15;291:119-120.
70. Impact of the new USA and ESC/ESH HTN guidelines for Spain. Ruilope LM, Ruiz-Hurtado G. Eur Heart J. 2019 Jun 1;40(21):1660-1661.
69. Frequency and Prognosis of Treated Hypertensive Patients According to Prior and New Blood Pressure Goals. Ruilope LM, Ruiz-Hurtado G, Barderas MG, de la Cruz JJ, Lucia A, de la Sierra A, Gorostidi M, Vinyoles E, Segura J, Solís J, Arribas F, García-Puig J, Tamargo J, O'Brien E, Volpe M, Whelton PK, Williams B, Banegas JR. Hypertension. 2019 Jul;74(1):130-136.
68. Gender-Dependent Alteration of Ca2+ and TNFα Signaling in db/db Mice, an Obesity-Linked Type 2 Diabetic Model. Delgado C, Gomez AM, Samia El Hayek M, Ruiz-Hurtado G, Pereira L. Front Physiol. 2019 Feb 7;10:40.
67. Urine Haptoglobin and Haptoglobin-Related Protein Predict Response to Spironolactone in Patients With Resistant Hypertension. Martin-Lorenzo M, Martinez PJ, Baldan-Martin M, Lopez JA, Minguez P, Santiago-Hernandez A, Vazquez J, Segura J, Ruiz-Hurtado G, Vivanco F, Barderas MG, Ruilope LM, Alvarez-Llamas G. Hypertension. 2019 Apr;73(4):794-802.
66. Identification of six cardiovascular risk biomarkers in the young population: A promising tool for early prevention. Martínez PJ, Baldán-Martín M, López JA, Martín-Lorenzo M, Santiago-Hernández A, Agudiez M, Cabrera M, Calvo E, Vázquez J, Ruiz-Hurtado G, Vivanco F, Ruilope LM, Barderas MG, Alvarez-Llamas G. Atherosclerosis. 2019 Mar;282:67-74.
65. New vascular biomarkers related to ABPM phenotypes in untreated patients. Ruilope LM, Ruiz-Hurtado G. J Clin Hypertens (Greenwich). 2019 Jan;21(1):53-54.
64. Impaired Mitophagy and Protein Acetylation Levels in Fibroblasts from Parkinson's Disease Patients. Yakhine-Diop SMS, Niso-Santano M, Rodríguez-Arribas M, Gómez-Sánchez R, Martínez-Chacón G, Uribe-Carretero E, Navarro-García JA, Ruiz-Hurtado G, Aiastui A, Cooper JM, López de Munaín A, Bravo-San Pedro JM, González-Polo RA, Fuentes JM. Mol Neurobiol. 2019 Apr;56(4):2466-2481.
63. Association between renal dysfunction and metalloproteinase (MMP)-9 activity in hypertensive patients. Rodríguez-Sánchez E, Navarro-García JA, Aceves-Ripoll J, Álvarez-Llamas G, Segura J, Barderas MG, Ruilope LM, Ruiz-Hurtado G. Nefrologia. 2019 Mar - Apr;39(2):184-191
62. Fibroblast growth factor-23 promotes rhythm alterations and contractile dysfunction in adult ventricular cardiomyocytes. Navarro-García JA, Delgado C, Fernández-Velasco M, Val-Blasco A, Rodríguez-Sánchez E, Aceves-Ripoll J, Gómez-Hurtado N, Bada-Bosch T, Mérida-Herrero E, Hernández E, Praga M, Salguero R, Solís J, Arribas F, Delgado JF, Bueno H, Kuro-O M, Ruilope LM, Ruiz-Hurtado G. Nephrol Dial Trasp. 2019 Jan 19. doi: 10.1093/ndt/gfy392
2018
61. Translational science in albuminuria: a new view of de novo albuminuria under chronic RAS suppression. Baldan-Martin M, Rodríguez-Sánchez E, González-Calero L, Ruilope LM, Alvarez-Llamas G, Barderas MG, Ruiz-Hurtado G. Clin Sci (Lond). 2018 Apr 6;132(7):739-758. See Pubmed
60. Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals. Baldan-Martin M, Lopez JA, Corbacho-Alonso N, Martinez PJ, Rodriguez-Sanchez E, Mourino-Alvarez L, Sastre-Oliva T, Martin-Rojas T, Rincón R, Calvo E, Vazquez J, Vivanco F, Padial LR, Alvarez-Llamas G, Ruiz-Hurtado G, Ruilope LM, Barderas MG. Sci Rep. 2018 Mar 19;8(1):4802. See Pubmed
59. Specific Activation of the Alternative Cardiac Promoter of Cacna1c by the Mineralocorticoid Receptor. Mesquita TR, Auguste G, Falcón D, Ruiz-Hurtado G, Salazar-Enciso R, Sabourin J, Lefebvre F, Viengchareun S, Kobeissy H, Lechène P, Nicolas V, Fernandez-Celis A, Gómez S, Lauton Santos S, Morel E, Rueda A, López-Andrés N, Gómez AM, Lombès M, Benitah JP. Circ Res. 2018 Mar 30;122(7):e49-e61. See Pubmed
58. PTH, vitamin D, and the FGF-23-klotho axis and heart: going beyond the confines of nephrology. Navarro-García JA, Fernández-Velasco M, Delgado C, Delgado JF, Kuro-O M, Ruilope LM, Ruiz-Hurtado G. Eur J Clin Invest. 2018 Feb 2. 2018 Apr;48(4). See Pubmed
2017
57. Advantages of sacubitril/valsartan beyond blood pressure control in arterial hypertension. Ruiz-Hurtado G, Ruilope LM. Eur Heart J. 2017 Nov 21;38(44):3318-3320. See Pubmed
56. Citric Acid Metabolism in Resistant Hypertension: Underlying Mechanisms and Metabolic Prediction of Treatment Response. Martin-Lorenzo M, Martinez PJ, Baldan-Martin M, Ruiz-Hurtado G, Prado JC, Segura J, de la Cuesta F, Barderas MG, Vivanco F, Ruilope LM, Alvarez-Llamas G. Hypertension. 2017 Nov;70(5):1049-1056.
55. Immune system deregulation in hypertensive patients chronically RAS suppressed developing albuminuria. Martin-Lorenzo M, Gonzalez-Calero L, Martinez PJ, Baldan-Martin M, Lopez JA, Ruiz-Hurtado G, de la Cuesta F, Segura J, Vazquez J, Vivanco F, Barderas MG, Ruilope LM, Alvarez-Llamas G. Sci Rep. 2017 21;7(1):8894. Original.
54. Rapid, automated and specific immunoassay to directly measure MMP-9-TIMP-1 interactions in human plasma using AlphaLISA technology: a new alternative to classical ELISA. Pulido-Olmo H, Rodríguez-Sánchez E, Navarro-García JA, Barderas MG, Álvarez-Llamas G, Segura J, Fernández-Alfonso MS, Ruilope LM, Ruiz-Hurtado G. Frontiers in Immunology. 2017 24;8:853. Original.
53. Proteomic Analysis of Blood Extracellular Vesicles in Cardiovascular Disease by LC- MS/MS Analysis. Baldan-Martin M, de la Cuesta F, Alvarez-Llamas G, Ruiz-Hurtado G, Ruilope LM, Barderas MG. Methods Mol Biol. 2017;1619:141-149.
52. Urinary exosomes reveal protein signatures in hypertensive patients with albuminuria. Gonzalez-Calero L, Martínez PJ, Martin-Lorenzo M, Baldan-Martin M, Ruiz-Hurtado G, de la Cuesta F, Calvo E, Segura J, Lopez JA, Vázquez J, Barderas MG, Ruilope LM, Vivanco F, Alvarez-Llamas G. Oncotarget. 2017 May 11. doi: 10.18632/oncotarget.17787. Original.
51. The impact of antihypertensives on kidney disease. Marquez DF, Ruiz-Hurtado G, Ruilope L. F1000Res. 2017 May 2;6:611. eCollection 2017. Review.
50. Has the SPRINT trial introduced a new blood-pressure goal in hypertension? Ruiz-Hurtado G, Banegas JR, Sarafidis PA, Volpe M, Williams B, Ruilope LM. Nat Rev Cardiol. 2017 May 11.
49. Microvascular injury and the kidney in hypertension. Ruiz-Hurtado G, Ruilope LM. Hipertens Riesgo Vasc. 2017 Apr 18. pii: S1889-1837(17)30021-1. Editorial.
48. Sacubitril/valsartan in the treatment of arterial hypertension: an unaccomplished promise? Ruiz-Hurtado G, Ruilope LM. Hypertens Res. 2017 May;40(5):439-440. Editorial.
47. Mild and Short-Term Caloric Restriction Prevents Obesity-Induced Cardiomyopathy in Young Zucker Rats without Changing in Metabolites and Fatty Acids Cardiac Profile. Ruiz-Hurtado G, García-Prieto CF, Pulido-Olmo H, Velasco-Martín JP, Villa-Valverde P, Fernández-Valle ME, Boscá L, Fernández-Velasco M, Regadera J, Somoza B, Fernández-Alfonso MS. Front Physiol. 2017 Feb 1;8:42. eCollection 2017. Original.
46. Kalirin and CHD7: novel endothelial dysfunction indicators in circulating extracellular vesicles from hypertensive patients with albuminuria. de la Cuesta F, Baldan-Martin M, Moreno-Luna R, Alvarez-Llamas G, Gonzalez-Calero L, Mourino-Alvarez L, Sastre-Oliva T, López JA, Vázquez J, Ruiz-Hurtado G, Segura J, Vivanco F, Ruilope LM, Barderas MG. Oncotarget. 2017 Feb 28;8(9):15553-15562. Original.
45. Role of NOD1 in Heart Failure Progression via Regulation of Ca2+ Handling. Val-Blasco A, Piedras MJ, Ruiz-Hurtado G, Suarez N, Prieto P, Gonzalez-Ramos S, Gómez-Hurtado N, Delgado C, Pereira L, Benito G, Zaragoza C, Domenech N, Crespo-Leiro MG, Vasquez-Echeverri D, Nuñez G, Lopez-Collazo E, Boscá L, Fernández-Velasco M. J Am Coll Cardiol. 2017 Jan 31;69(4):423-433. Original.
44. 24-h pulse pressure cutoff point definition by office pulse pressure in a population of Spanish older hypertensive patients. Vinyoles E, de la Sierra A, Roso-Llorach A, Banegas JR, de la Cruz JJ, Gorostidi M, Segura J, Divisón JA, Ruíz-Hurtado G, Ruilope LM; Spanish ABPM Registry Investigators. J Hypertens. 2017 May;35(5):1011-1018. Original.
2016
43. Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME. Sarafidis PA, Lazaridis AA, Ruiz-Hurtado G, Ruilope LM. Nat Rev Endocrinol. 2017 Jun;13(6):365-374. Review.
42. Improvement in cardiovascular prognosis of type 2 diabetes mellitus, is it a reality? Ruiz-Hurtado G, Vigil L, Ruilope LM. Hipertens Riesgo Vasc. 2016 Oct - Dec;33(4):123-125. Editorial.
41. Association Between High and Very High Albuminuria and Nighttime Blood Pressure: Influence of Diabetes and Chronic Kidney Disease. Ruiz-Hurtado G, Ruilope LM, de la Sierra A, Sarafidis P, de la Cruz JJ, Gorostidi M, Segura J, Vinyoles E, Banegas JR. Diabetes Care. 2016 Oct;39(10):1729-37. Original.
40. Hypertensive patients exhibit an altered metabolism. A specific metabolite signature in urine is able to predict albuminuria progression. Gonzalez-Calero L, Martin-Lorenzo M, Martínez PJ, Baldan-Martin M, Ruiz-Hurtado G, Segura J, de la Cuesta F, Barderas MG, Ruilope LM, Vivanco F, Alvarez-Llamas G. Transl Res. 2016 Dec;178:25-37.e7. Original.
39. Plasma Molecular Signatures in Hypertensive Patients With Renin-Angiotensin System Suppression: New Predictors of Renal Damage and De Novo Albuminuria Indicators. Baldan-Martin M, Mourino-Alvarez L, Gonzalez-Calero L, Moreno-Luna R, Sastre-Oliva T, Ruiz-Hurtado G, Segura J, Lopez JA, Vazquez J, Vivanco F, Alvarez-Llamas G, Ruilope LM, de la Cuesta F, Barderas MG. Hypertension. 2016 Jul;68(1):157-66. Original.
38. Global cardiovascular protection in chronic kidney disease. Ruiz-Hurtado G, Sarafidis P, Fernández-Alfonso MS, Waeber B, Ruilope LM. Nat Rev Cardiol. 2016 Oct;13(10):603-8. Review.
37. Cardiovascular risk study in patients with renin-angiotensin system blockade by means of the proteone of circulating extracellular vesicles. de la Cuesta F, Baldan-Martin M, Mourino-Alvarez L, Sastre-Oliva T, Alvarez-Llamas G, Gonzalez-Calero L, Ruiz-Hurtado G, Segura J, Vivanco F, Ruilope LM, Barderas MG. Hipertens Riesgo Vasc. 2016 Jan-Mar;33(1):21-7. Original.
36. Urinary alpha-1 antitrypsin and CD59 glycoprotein predict albuminuria development in hypertensive patients under chronic renin-angiotensin system suppression. Gonzalez-Calero L, Martin-Lorenzo M, de la Cuesta F, Maroto AS, Baldan-Martin M, Ruiz-Hurtado G, Pulido-Olmo H, Segura J, Barderas MG, Ruilope LM, Vivanco F, Alvarez-Llamas G. Cardiovasc Diabetol. 2016 Jan 16;15:8. Original.
35. Role of matrix metalloproteinase-9 in chronic kidney disease: a new biomarker of resistant albuminuria. Pulido-Olmo H, García-Prieto CF, Álvarez-Llamas G, Barderas MG, Vivanco F, Aranguez I, Somoza B, Segura J, Kreutz R, Fernández-Alfonso MS, Ruilope LM, Ruiz-Hurtado G. Clin Sci (Lond). 2016 Apr 1;130(7):525-38. Original.
34. New Strategy to Control Blood Pressure: Interactive Mobile Phone Support. Ruiz-Hurtado G, Ruilope LM. J Clin Hypertens (Greenwich). 2016 Feb;18(2):109-10. Editorial.
2015
33. Salutary cardiovascular effects of antidiabetic drugs: myth or fact? Ruiz-Hurtado G, Ruilope LM. J Hypertens. 2015 Nov;33(11):2198-9. Editorial.
32. An update of the blockade of the renin angiotensin aldosterone system in clinical practice. Márquez DF, Ruiz-Hurtado G, Ruilope LM, Segura J. Expert Opin Pharmacother. 2015;16(15):2283-92. Review.
31. Ambulatory and home blood pressure monitoring in people with chronic kidney disease. Time to abandon clinic blood pressure measurements? Ruiz-Hurtado G, Gorostidi M, Waeber B, Ruilope LM. Curr Opin Nephrol Hypertens. 2015 Nov;24(6):488-91. Review.
30. Reconciling depressed Ca2+ sparks occurrence with enhanced RyR2 activity in failing mice cardiomyocytes. Ruiz-Hurtado G, Li L, Fernández-Velasco M, Rueda A, Lefebvre F, Wang Y, Mateo P, Cassan C, Gellen B, Benitah JP, Gómez AM. J Gen Physiol. 2015 Oct;146(4):295-306. Original.
29. Fetal undernutrition is associated with perinatal sex-dependent alterations in oxidative status. Rodríguez-Rodríguez P, de Pablo AL, Condezo-Hoyos L, Martín-Cabrejas MA, Aguilera Y, Ruiz-Hurtado G, Gutierrez-Arzapalo PY, Ramiro-Cortijo D, Fernández-Alfonso MS, González Mdel C, Arribas SM. J Nutr Biochem. 2015 Dec;26(12):1650-9. Original.
28. Proarrhythmic effect of sustained EPAC activation on TRPC3/4 in rat ventricular cardiomyocytes. Domínguez-Rodríguez A, Ruiz-Hurtado G, Sabourin J, Gómez AM, Alvarez JL, Benitah JP. J Mol Cell Cardiol. 2015 Oct;87:74-8. Original.
27. Prediction of development and maintenance of high albuminuria during chronic renin-angiotensin suppression by plasma proteomics. Baldan-Martin M, de la Cuesta F, Alvarez-Llamas G, Gonzalez-Calero L, Ruiz-Hurtado G, Moreno-Luna R, Mourino-Alvarez L, Sastre-Oliva T, Segura J, Padial LR, Vivanco F, Ruilope LM, Barderas MG. Int J Cardiol. 2015 Oct 1;196:170-7. Original
26. 8D.08: Matrix metalloproteinase (MMP) 2 and MMP9 activity is increased in conditionsof albuminuria escape under chronic renin-angiotensinsystem suppression. Pulido-Olmo H, Gracia-Prieto CF, Somoza B, Aránguez I, Alvarez-Llamas G, Vivanco F, Barderas MG, Kreutz R, Segura J, Fernández-Alfonso MS, Ruilope LM, Ruiz-Hurtado G. J Hypertens. 2015 Jun;33 Suppl 1:e115-6.
25. Genetic predisposition to albuminuria is associated with increased arterial stiffness: role of elastin. Gil-Ortega M, García-Prieto CF, Ruiz-Hurtado G, Steireif C, González MC, Schulz A, Kreutz R, Fernández-Alfonso MS, Arribas S, Somoza B. Br J Pharmacol. 2015 Sep;172(17):4406-18. Original.
24. NOD1, a new player in cardiac function and calcium handling. Delgado C, Ruiz-Hurtado G, Gómez-Hurtado N, González-Ramos S, Rueda A, Benito G, Prieto P, Zaragoza C, Delicado EG, Pérez-Sen R, Miras-Portugal MT, Núñez G, Boscá L, Fernández-Velasco M. Cardiovasc Res. 2015 Jun 1;106(3):375-86. Original.
23. Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats. Ruiz-Hurtado G, Ruilope LM. Eur Heart J Cardiovasc Pharmacother. 2015 Apr;1(2):126-31. Review.
22. Mild caloric restriction reduces blood pressure and activates endothelial AMPK-PI3K-Akt-eNOS pathway in obese Zucker rats. García-Prieto CF, Pulido-Olmo H, Ruiz-Hurtado G, Gil-Ortega M, Aranguez I, Rubio MA, Ruiz-Gayo M, Somoza B, Fernández-Alfonso MS. Vascul Pharmacol. 2015 Feb-Mar;65-66:3-12. Original.
21. High-fat diet induces endothelial dysfunction through a down-regulation of the endothelial AMPK-PI3K-Akt-eNOS pathway. García-Prieto CF, Hernández-Nuño F, Rio DD, Ruiz-Hurtado G, Aránguez I, Ruiz-Gayo M, Somoza B, Fernández-Alfonso MS. Mol Nutr Food Res. 2015 Mar;59(3):520-32. Original.
2014
20. Ca(2+) handling alterations and vascular dysfunction in diabetes. Fernández-Velasco M, Ruiz-Hurtado G, Gómez AM, Rueda A. Cell Calcium. 2014 Nov;56(5):397-407. Review.
19. Calcium signaling in diabetic cardiomyocytes. Pereira L, Ruiz-Hurtado G, Rueda A, Mercadier JJ, Benitah JP, Gómez AM. Cell Calcium. 2014 Nov;56(5):372-80. Review.
18. Development of albuminuria and enhancement of oxidative stress during chronic renin-angiotensin system suppression. Ruiz-Hurtado G, Condezo-Hoyos L, Pulido-Olmo H, Aranguez I, Del Carmen Gónzalez M, Arribas S, Cerezo C, Segura J, Praga M, Fernández-Alfonso MS, Ruilope LM. J Hypertens. 2014 Oct;32(10):2082-91; discussion 2091. Original.
17. Does cardiovascular protection translate into renal protection? Ruiz-Hurtado G, Ruilope LM. Nat Rev Cardiol. 2014 Dec;11(12):742-6. Review.
16. Hypertension and obesity: correlates with renin-angiotensin-aldosterone system and uric acid. Ruiz-Hurtado G, Ruilope LM. J Clin Hypertens (Greenwich). 2014 Aug;16(8):559-60. Editorial.
2013
15. Ca(2+) fluxes involvement in gene expression during cardiac hypertrophy. Gómez AM, Ruiz-Hurtado G, Benitah JP, Domínguez-Rodríguez A. Curr Vasc Pharmacol. 2013 Jul;11(4):497-506. Review.
14. Dissecting the genetic predisposition to albuminuria and endothelial dysfunction in a genetic rat model. Steireif C, García-Prieto CF, Ruiz-Hurtado G, Pulido-Olmo H, Aranguez I, Gil-Ortega M, Somoza B, Schönfelder G, Schulz A, Fernández-Alfonso MS, Kreutz R. J Hypertens. 2013 Nov;31(11):2203-12; discussion 2212. Original.
2012
13. The other side of cardiac Ca(2+) signaling: transcriptional control. Domínguez-Rodríguez A, Ruiz-Hurtado G, Benitah JP, Gómez AM. Front Physiol. 2012 Nov 28;3:452. Review.
12. Epac in cardiac calcium signaling. Ruiz-Hurtado G, Morel E, Domínguez-Rodríguez A, Llach A, Lezoualc'h F, Benitah JP, Gomez AM. J Mol Cell Cardiol. 2013 May;58:162-71. Review.
11. Sustained Epac activation induces calmodulin dependent positive inotropic effect in adult cardiomyocytes. Ruiz-Hurtado G, Domínguez-Rodríguez A, Pereira L, Fernández-Velasco M, Cassan C, Lezoualc'h F, Benitah JP, Gómez AM. J Mol Cell Cardiol. 2012 Nov;53(5):617-25. Original.
10. Cardiotrophin-1 induces sarcoplasmic reticulum Ca(2+) leak and arrhythmogenesis in adult rat ventricular myocytes. Ruiz-Hurtado G, Gómez-Hurtado N, Fernández-Velasco M, Calderón E, Smani T, Ordoñez A, Cachofeiro V, Boscá L, Díez J, Gómez AM, Delgado C. Cardiovasc Res. 2012 Oct 1;96(1):81-9. Original.
9. Epac enhances excitation-transcription coupling in cardiac myocytes. Pereira L, Ruiz-Hurtado G, Morel E, Laurent AC, Métrich M, Domínguez-Rodríguez A, Lauton-Santos S, Lucas A, Benitah JP, Bers DM, Lezoualc'h F, Gómez AM. J Mol Cell Cardiol. 2012 Jan;52(1):283-91. Original.
2011
8. RyRCa2+ leak limits cardiac Ca2+ window current overcoming the tonic effect of calmodulinin mice. Fernández-Velasco M, Ruiz-Hurtado G, Rueda A, Neco P, Mercado-Morales M, Delgado C, Napolitano C, Priori SG, Richard S, Gómez AM, Benitah JP. PLoS One. 2011;6(6):e20863. Original.
7. Cardioprotective action of urocortin in postconditioning involves recovery of intracellular calcium handling. Calderón-Sánchez EM, Ruiz-Hurtado G, Smani T, Delgado C, Benitah JP, Gómez AM, Ordóñez A. Cell Calcium. 2011 Jul;50(1):84-90. Original.
2010
6. Nitric oxide pathway in hypertrophied heart: new therapeutic uses of nitric oxide donors. Ruiz-Hurtado G, Delgado C. J Hypertens. 2010 Sep;28 Suppl 1:S56-61. Review.
2009
5. Urocortin induces positive inotropic effect in rat heart. Calderón-Sanchez E, Delgado C, Ruiz-Hurtado G, Domínguez-Rodríguez A, Cachofeiro V, Rodríguez-Moyano M, Gomez AM, Ordóñez A, Smani T. Cardiovasc Res. 2009 Sep 1;83(4):717-25. Original.
4. Cardiac L-type calcium current is increased in a model of hyperaldosteronism in the rat. Martin-Fernandez B, Miana M, De Las Heras N, Ruiz-Hurtado G, Fernandez-Velasco M, Bas M, Ballesteros S, Lahera V, Cachofeiro V, Delgado C. Exp Physiol. 2009 Jun;94(6):675-83. Original.
2007
3. LA419, a novel nitric oxide donor, prevents pathological cardiac remodeling in pressure-overloaded rats via endothelial nitric oxide synthase pathway regulation. Ruiz-Hurtado G, Fernández-Velasco M, Mourelle M, Delgado C. Hypertension. 2007 Dec;50(6):1049-56. Original.
2. TNF-alpha downregulates transient outward potassium current in rat ventricular myocytes through iNOS overexpression and oxidant species generation. Fernández-Velasco M, Ruiz-Hurtado G, Hurtado O, Moro MA, Delgado C. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H238-45. Original.
2006
1. I K1 and I f in ventricular myocytes isolated from control and hypertrophied rat hearts. Fernández-Velasco M, Ruiz-Hurtado G, Delgado C. Pflugers Arch. 2006 May;452(2):146-54. Original.
Websites:
https://www.researchgate.net/profile/Gema_Ruiz-Hurtado
https://orcid.org/0000-0003-3482-0915
https://publons.com/researcher/2799580/gema-ruiz-hurtado/
Others News:
Book Chapters:
1. HYPERTENSION IN LATIN/HISPANIC POPULATION. LM Ruilope; JR Banegas; Gema Ruiz-Hurtado. Hypertension: a Companion to Braunwald‘s Heart Disease. 2016.
2. CARDIACARRHYTHMIAS-NEW CONSIDERATIONS. Gema Ruiz-Hurtado; JL Álvarez; JP Benitah. L-type Ca2+ current in cardiac arrhythmias. INTECH. ISBN 978 953 51 0126 0. 2012.